These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20007362)

  • 1. Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.
    Maves RC; Castillo Oré RM; Porter KR; Kochel TJ
    Clin Vaccine Immunol; 2010 Feb; 17(2):304-6. PubMed ID: 20007362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys.
    Maves RC; Oré RM; Porter KR; Kochel TJ
    Vaccine; 2011 Mar; 29(15):2691-6. PubMed ID: 21303709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates.
    Sundaram AK; Ewing D; Blevins M; Liang Z; Sink S; Lassan J; Raviprakash K; Defang G; Williams M; Porter KR; Sanders JW
    Vaccine; 2020 Apr; 38(17):3313-3320. PubMed ID: 32184032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.
    Raviprakash K; Sun P; Raviv Y; Luke T; Martin N; Kochel T
    Hum Vaccin Immunother; 2013 Nov; 9(11):2336-41. PubMed ID: 23835446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.
    Diaz C; Lin L; Martinez LJ; Eckels KH; Campos M; Jarman RG; De La Barrera R; Lepine E; Toussaint JF; Febo I; Innis BL; Thomas SJ; Schmidt AC
    Am J Trop Med Hyg; 2018 May; 98(5):1435-1443. PubMed ID: 29512481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.
    Fernandez S; Thomas SJ; De La Barrera R; Im-Erbsin R; Jarman RG; Baras B; Toussaint JF; Mossman S; Innis BL; Schmidt A; Malice MP; Festraets P; Warter L; Putnak JR; Eckels KH
    Am J Trop Med Hyg; 2015 Apr; 92(4):698-708. PubMed ID: 25646261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.
    Gil L; Marcos E; Izquierdo A; Lazo L; Valdés I; Ambala P; Ochola L; Hitler R; Suzarte E; Álvarez M; Kimiti P; Ndung'u J; Kariuki T; Guzmán MG; Guillén G; Hermida L
    Immunol Cell Biol; 2015 Jan; 93(1):57-66. PubMed ID: 25178969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice.
    Zuest R; Valdes I; Skibinski D; Lin Y; Toh YX; Chan K; Hermida L; Connolly J; Guillen G; Fink K
    Vaccine; 2015 Mar; 33(12):1474-82. PubMed ID: 25659270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice.
    Lazo L; Gil L; López C; Valdés I; Blanco A; Pavón A; Romero Y; Guzmán MG; Guillén G; Hermida L
    Acta Trop; 2012 Nov; 124(2):107-12. PubMed ID: 22750482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells.
    Suphatrakul A; Yasanga T; Keelapang P; Sriburi R; Roytrakul T; Pulmanausahakul R; Utaipat U; Kawilapan Y; Puttikhunt C; Kasinrerk W; Yoksan S; Auewarakul P; Malasit P; Charoensri N; Sittisombut N
    Vaccine; 2015 Oct; 33(42):5613-5622. PubMed ID: 26382602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
    Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
    Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.
    Batra G; Raut R; Dahiya S; Kamran N; Swaminathan S; Khanna N
    J Virol Methods; 2010 Jul; 167(1):10-6. PubMed ID: 20211204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines.
    Borges MB; Marchevsky RS; Carvalho Pereira R; da Silva Mendes Y; Almeida Mendes LG; Diniz-Mendes L; Cruz MA; Tahmaoui O; Baudart S; Freire M; Homma A; Schneider-Ohrum K; Vaughn DW; Vanloubbeeck Y; Lorin C; Malice MP; Caride E; Warter L
    PLoS Pathog; 2019 Apr; 15(4):e1007721. PubMed ID: 31009499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice.
    Hunsawong T; Sunintaboon P; Warit S; Thaisomboonsuk B; Jarman RG; Yoon IK; Ubol S; Fernandez S
    Vaccine; 2015 Mar; 33(14):1702-10. PubMed ID: 25701315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
    Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
    Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
    Martinez DR; Metz SW; Baric RS
    Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
    Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
    Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.